Zacks Investment ResearchWed, 13 May 2026 13:20:27 GMTUpstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue EstimatesUPB+4.58%
BenzingaThu, 26 Mar 2026 17:10:33 GMTUpstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 DataUPB+4.58%
BenzingaFri, 13 Feb 2026 15:45:35 GMTUpstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge ConcernsUPB+4.58%